Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer

JAMA Oncol. 2021 Jun 1;7(6):937-939. doi: 10.1001/jamaoncol.2021.0546.

Abstract

This cohort study examines the association of KRAS status with outcomes following immune checkpoint inhibition monotherapy vs chemoimmunotherapy.

MeSH terms

  • B7-H1 Antigen / metabolism
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Humans
  • Immune Checkpoint Inhibitors
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics

Substances

  • B7-H1 Antigen
  • Immune Checkpoint Inhibitors
  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)